Shibata, M <br/><br/>
Effect of magnesium sulfate pretreatment and significance of matrix metalloproteinase-1 and interleukin-6 levels in coronary reperfusion therapy for patients with acute myocardial infarction.  [electronic resource] 

 -  Angiology  Jul 1999 
 - 573-82 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0003-3197 
<br/><br/><label>Standard No.: </label>10.1177/000331979905000707  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Angina Pectoris--etiology<br/>Angioplasty, Balloon, Coronary<br/>Arrhythmias, Cardiac--etiology<br/>Calcium--metabolism<br/>Calcium Channel Blockers--administration & dosage<br/>Collagenases--blood<br/>Complement System Proteins--drug effects<br/>Electrocardiography--drug effects<br/>Female<br/>Fibrinolytic Agents--therapeutic use<br/>Humans<br/>Incidence<br/>Injections, Intravenous<br/>Interleukin-6--blood<br/>Magnesium--blood<br/>Magnesium Sulfate--administration & dosage<br/>Male<br/>Matrix Metalloproteinase 1<br/>Middle Aged<br/>Muscle, Smooth, Vascular--drug effects<br/>Myocardial Infarction--drug therapy<br/>Myocardial Reperfusion Injury--etiology<br/>Myocardium--metabolism<br/>Placebos<br/>Premedication<br/>Recurrence<br/>Thrombolytic Therapy<br/>Tissue Plasminogen Activator--therapeutic use